Skip to main content
SpringerLink
Log in

Prognostication of Functional Outcomes of Schizophrenia Using a Multigene Panel

  • Published:
Neuroscience and Behavioral Physiology Aims and scope Submit manuscript

Objectives. To compare groups of schizophrenia patients with different levels of functional outcomes and different frequencies of risk variants at polymorphic loci of five candidate genes to create a multigene panel and to test its predictive value for long-term disease outcomes. Materials and methods. Patients included in this study were divided in terms of the typology used here into three groups with different levels of social functioning. Group 1 patients had the highest levels, while values were significantly lower in group 2 and lowest in group 3. The multigene panel included genes for the type 2A serotonin receptor (5-HTR2a T102C), the serotonin transporter (5-HTTLPR), C-reactive protein (CRP-717A>G), the type 1 angiotensin II receptor (AGTR1 A1166C), and brain-derived neurotrophic factor (BDNF Val66Met). Computation of multigene risk (MGR) was by summation of all the risk alleles carried by a particular patient. For each polymorphism, carriers of the genotype homozygous at the high-risk allele had a value of 2 and heterozygotes had a value of 1; homozygotes at the low-risk allele had a value of 0. MGR Values for a patient could range from 0 to 10 risk alleles. Results. Group was found to have a significant effect on MGR (p < 0.0001). Between-group differences were also significant (p < 0.01). Group 1 contained no carriers of six or more risk alleles and more than 50% were carriers of fewer than five alleles. In group 2, 19.4% of patients were carriers of ≥6 risk alleles, while 31.7% of patients in group 3 carried ≥6 risk alleles. These groups had no carriers of 0–2 risk alleles, while 20.7% of patients group 1 carried 0–2 risk alleles. Conclusions. MGR may be a predictor of functional outcome in schizophrenia patients. Low levels of risk alleles (0–4) allowed individuals to be predicted with high probability to have favorable functional outcome in the long-term period of illness.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. G. Harrison, K. Hopper, T. Craig, et al., “Recovery from psychotic illness: a 15- and 25-year international follow-up study,” Br. J. Psychiatry, 178, 506–517 (2001), https://doi.org/https://doi.org/10.1192/bjp.178.6.506.

  2. S. N. Mosolov, A. V. Potapov, Yu. V. Ushakov, et al., “Standardized clinical-functional criteria for therapeutic remission in schizophrenia: development and validation,” Psikhiatr. Psikhofarmakoter., 14, No. 2, 9–19 (2012).

    Google Scholar 

  3. P. Jones and R. M. Murray, “The genetics of schizophrenia is the genetics of neurodevelopment,” Br. J. Psychiatry, 158, 615–623 (2001), https://doi.org/https://doi.org/10.1192/bjp.158.5.615.

  4. S. A. Golubev and V. G. Kaleda, “Characteristics of the long-term course of illness in patient with adolescent-onset schizophrenia,” Zh. Nevrol. Psikhiatr., 120, No. 6, Iss. 2, 23–30 (2020), https://doi.org/10.17116/jnevro202012006223.

  5. S. Selvaraj, D. Arnone, A. Cappai, and O. Howes, “Alterations in the serotonin system in schizophrenia: a systematic review and meta-analysis of postmortem and molecular imaging studies,” Neurosci. Biobehav. Rev., 45, 233–245 (2014), https://doi.org/https://doi.org/10.1016/j.neubiorev.2014.06.005.

  6. R. H. Segman, U. Heresco-Levy, B. Finkel, et al., “Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia,” Mol. Psychiatry, 6, No. 2, 225–229 (2001), https://doi.org/https://doi.org/10.1038/sj.mp.4000842.

  7. H. M. Abdolmaleky, S. V. Faraone, S. J. Glatt, and M. T. Tsuang, “Metaanalysis of association between the T102C polymorphism of the 5HT2a receptor gene and schizophrenia,” Schizophr. Res., 67, No. 1, 53–62 (2004), https://doi.org/https://doi.org/10.1016/S0920-9964(03)00183-X.

  8. V. E. Golimbet, O. M. Lavrushina, V. G. Kaleda, et al., “Supportive evidence for the association between the T102C 5-HTR2A gene polymorphism and schizophrenia: a large-scale case-control and family-based study,” Eur. Psychiatry, 22, No. 3, 167–170 (2007), https://doi.org/https://doi.org/10.1016/j.eurpsy.2006.06.002.

  9. S. F. Chen, Y. C. Shen, and C. H. Chen, “HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients,” Clinical Trial Psychopharmacology (Berl.), 205, No. 2, 285–292 (2009), https://doi.org/https://doi.org/10.1007/s00213-009-1538-z.

  10. J. Ni, W. Lu, Z. Wu, et al., “T102C polymorphism of serotonin 2A type receptor gene confers susceptibility to (early onset) schizophrenia in Han Chinese: an association study and meta-analysis,” Asia Pac. Psychiatry, 5, No. 1, 24–30 (2013), https://doi.org/https://doi.org/10.1111/appy.12027.

  11. V. E. Golimbet, V. G. Kaleda, G. I. Korovaitseva, et al., “Genetic polymorphisms associated with different extents of premorbid personality anomalies in schizophrenia patients,” Zh. Nevrol. Psikhiatr., 119, No. 3, 55–59 (2019), https://doi.org/https://doi.org/10.17116/jnevro201911903155.

  12. T. E. Goldberg, R. Kotov, A. T. Lee, et al., “The serotonin transporter gene and disease modification in psychosis: evidence for systematic differences in allelic directionality at the 5-HTTLPR locus,” Schizophr. Res., 111, No. 1–3, 103–108 (2009), https://doi.org/https://doi.org/10.1016/j.schres.2009.03.021.

  13. V. Golimbet, G. Korovaitseva, T. Lezheiko, et al., “The serotonin transporter gene 5-HTTLPR polymorphism is associated with affective psychoses but not with schizophrenia: A large-scale study in the Russian population,” J. Affect. Disord., 208, 604–609 (2017), https://doi.org/https://doi.org/10.1016/j.jad.2016.10.020.

  14. X. Fan, C. Pristach, E. Y. Liu, et al., “Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia,” Psychiatry Res., 149, No. 1–3, 267–271 (2007), https://doi.org/https://doi.org/10.1016/j.psychres.2006.07.011.

  15. T. Boozalis, A. L. Teixeira, R. Y. Cho, and O. Okusaga, “C-reactive protein correlates with negative symptoms in patients with schizophrenia,” Front. Public Health, 5, 360 (2018), https://doi.org/https://doi.org/10.3389/fpubh.2017.00360.

  16. M. V. Alfimova, V. E. Golimbet, T. V. Lezheiko, and N. V. Kondrat’ev, “Association of -717A>G polymorphism in the C-reactive protein gene (CRP) with schizotypal personality traits,” Bull. Exp. Biol. Med., 162, No. 1, 86–88 (2016), https://doi.org/https://doi.org/10.1007/s10517-016-3552-6.

  17. M. V. Alfimova, T. V. Lezheiko, S. V. Smirnova, et al., “Effect of the C-reactive protein gene on risk and clinical characteristics of schizophrenia in winter-born individuals,” Eur. Neuropsychopharmacol., 35, 81–88 (2020), https://doi.org/https://doi.org/10.1016/j.euroneuro.2020.03.014.

  18. S. J. Oh and X. Fan, “The possible role of the angiotensin system in the pathophysiology of schizophrenia: Implications for pharmacotherapy,” CNS Drugs, 33, No. 6, 539–547 (2019), https://doi.org/https://doi.org/10.1007/s40263-019-00632-4.

  19. W. D. Taylor, S. Benjamin, D. R. McQuoid, et al., “AGTR1 gene variation: Association with depression and frontotemporal morphology,” Psychiatry Res., 202, No. 2, 104–109 (2012), https://doi.org/https://doi.org/10.1016/j.pscychresns.2012.03.007.

  20. M. V. Gabaeva, G. I. Korovaitseva, D. V. Tikhonov, et al., “Analysis of associations of the G1444A polymorphism of the PPARGC1 Agene and the A1166C polymorphism of the AGTR1 gene with premorbid personality traits in schizophrenia,” Psikhiatriya, 1, No. 77, 39–44 (2018), https://doi.org/https://doi.org/10.30629/2618-6667-2018-77-39-44.

  21. V. E. Golimbet, M. V. Alfimova, G. I. Korovaĭtseva, and T. V. Lezheĭko, “Modulating effect of Val66Met polymorphism of brain-derived neurotrophic factor gene on clinical and psychological characteristics of patients with schizophrenia,” Mol. Biol (Mosk.), 48, No. 1, 69–74 (2014), https://doi.org/https://doi.org/10.1134/s0026893314010038.

  22. M. Notaras, R. Hill, and M. van den Buuse, “A role for the BDNF gene Val66Met polymorphism in schizophrenia? A comprehensive review,” Neurosci. Biobehav. Rev., 51, 15–30 (2015), https://doi.org/https://doi.org/10.1016/j.neubiorev.2014.12.016.

  23. G. Mezquida, R. Penadés, B. Cabrera, et al., “Association of the brain-derived neurotrophic factor Val66Met polymorphism with negative symptoms severity, but not cognitive function, in first-episode schizophrenia spectrum disorders,” Eur. Psychiatry, 38, 61–69 (2016), https://doi.org/https://doi.org/10.1016/j.eurpsy.2016.04.011.

  24. X. Y. Zhang, D. C. Chen, Y. L. Tan, et al., “BDNF polymorphisms are associated with schizophrenia onset and positive symptoms,” Schizophr. Res., 170, No. 1, 41–47 (2016), https://doi.org/https://doi.org/10.1016/j.schres.2015.11.009.

  25. J. Eng, ROC Analysis: Web-Based Calculator for ROC Curves, Johns Hopkins University, Baltimore (2014), https://www.jrocfit.org.

  26. M. K. Dimick, J. Cazes, L. M. Fiksenbaum, et al., “Proof-of-concept study of a multi-gene risk score in adolescent bipolar disorder,” J. Affect. Disord., 262, 211–222 (2020), https://doi.org/https://doi.org/10.1016/j.jad.2019.11.009.

  27. E. Koyama, C. C. Zai, L. Bryushkova, et al., “Predicting risk of suicidal ideation in youth using a multigene panel for impulsive aggression,” Psychiatry Res., 285, 112726 (2020), https://doi.org/https://doi.org/10.1016/j.psychres.2019.112726.

Download references

Author information

Authors and Affiliations

  1. Mental Health Research Center, Moscow, Russia

    S. A. Golubev, T. V. Lezheiko, G. I. Korovaitseva, M. V. Gabaeva, N. Yu. Kolesina, V. G. Kaleda & V. E. Golimbet

  2. Gannushkin Psychiatric Clinical Hospital No. 4, Moscow Health Department, Moscow, Russia

    S. A. Golubev

  3. Alekseev Psychiatric Clinical Hospital No. 1, Moscow Health Department, Moscow, Russia

    V. E. Golimbet

Authors
  1. S. A. Golubev
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. V. Lezheiko
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. I. Korovaitseva
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. V. Gabaeva
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N. Yu. Kolesina
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. V. G. Kaleda
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. V. E. Golimbet
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to V. E. Golimbet.

Additional information

Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 121, No. 7, Iss. 1, pp. 70–76, July, 2021.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Golubev, S.A., Lezheiko, T.V., Korovaitseva, G.I. et al. Prognostication of Functional Outcomes of Schizophrenia Using a Multigene Panel. Neurosci Behav Physi 52, 471–476 (2022). https://doi.org/10.1007/s11055-022-01263-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11055-022-01263-x

Keywords

Search

Navigation